| Literature DB >> 35740396 |
Moon Sung Kang1, Haeni Lee1, Seung Jo Jeong2, Tae Joong Eom1, Jeesu Kim1, Dong-Wook Han1,2.
Abstract
Photoacoustic imaging using energy conversion from light to ultrasound waves has been developed as a powerful tool to investigate in vivo phenomena due to their complex characteristics. In photoacoustic imaging, endogenous chromophores such as oxygenated hemoglobin, deoxygenated hemoglobin, melanin, and lipid provide useful biomedical information at the molecular level. However, these intrinsic absorbers show strong absorbance only in visible or infrared optical windows and have limited light transmission, making them difficult to apply for clinical translation. Therefore, the development of novel exogenous contrast agents capable of increasing imaging depth while ensuring strong light absorption is required. We report here the application of carbon nanomaterials that exhibit unique physical, mechanical, and electrochemical properties as imaging probes in photoacoustic imaging. Classified into specific structures, carbon nanomaterials are synthesized with different substances according to the imaging purposes to modulate the absorption spectra and highly enhance photoacoustic signals. In addition, functional drugs can be loaded into the carbon nanomaterials composite, and effective in vivo monitoring and photothermal therapy can be performed with cell-specific targeting. Diverse applied cases suggest the high potential of carbon nanomaterial-based photoacoustic imaging in in vivo monitoring for clinical research.Entities:
Keywords: carbon nanomaterials; image-guided therapy; photoacoustic imaging; phototherapy
Year: 2022 PMID: 35740396 PMCID: PMC9219987 DOI: 10.3390/biomedicines10061374
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Figure 1Illustration of functionalized carbon nanomaterial for photoacoustic imaging and a multimodal theragnostic probe.
Figure 2Schematic diagram of the principles of the PA imaging technique. PA, photoacoustic; US, ultrasound; CNMs, carbon nanomaterials.
Performance benchmarks of representative results of OR-PAM, AR-PAM, and PACT. OR-PAM, optical-resolution photoacoustic microscopy; AR-PAM, acoustic-resolution photoacoustic microscopy; PACT, photoacoustic computed tomography; N/A, not available.
| Type | Lateral Resolution | Axial Resolution | Center Frequency | Imaging Depth | Application | Ref. |
|---|---|---|---|---|---|---|
| OR-PAM | 3.5 | 27 | 50 | 1.5 | Ear (mouse) | [ |
| 3 | 15 | 50 | 0.7 | Brain (mouse) | [ | |
| 5 | 15 | 100 | 0.7 | Ear (mouse) | [ | |
| 6 | 37.7 | 50 | N/A | Ear (mouse) | [ | |
| AR-PAM | 50 | 25 | 50 | 2.4 | Tumor (porcine stomach) | [ |
| 53 | 18 | 75 | 1.8 | Ear (mouse) | [ | |
| 130 | 57 | 30 | 11 | Internal organs (rat) | [ | |
| 590 | 150 | 5 | 25 | Internal organs (mouse) | [ | |
| PACT | 129 | 1490 | 2.25 | N/A | Brain (mouse) | [ |
| 525 | 124 | 21 | 27 | Femoral nerve (mouse) | [ | |
| 1000 | 400 | 50 | 50 | Tumor (mouse hindlimb) | [ | |
| 1200 | 205 | 3–12 | 30 | Internal organs (rat) | [ |
Figure 3Schematic illustrations of PAM. (A) Scanning mechanism of PAM. (B) PA MAP image generation from volumetric data. (C) The optical and acoustic foci in OR-PAM and AR-PAM. PA, photoacoustic; PAM, photoacoustic microscopy; US, ultrasound; MAP, maximum amplitude projection; OR-PAM, optical-resolution PAM; AR-PAM, acoustic-resolution PAM.
Figure 4Schematic illustration of PACT. (A) PACT with a rotational scanning of a single-element US transducer. (B) PACT with a ring array transducer. PACT, photoacoustic computed tomography; US, ultrasound.
Figure 5rGO–AuNRs for PAI application. (A) Synthesis and characterization of rGO–AuNRs and in vivo mouse PAI. (B) Representative PA images obtained at 700 and 800 nm laser irradiation and (C) corresponding PA amplitude. UV–visible spectra (D) before and (E) after laser illumination for 5 min (20 mJ/cm2, 10 Hz). (F) PA images visualized after illumination with different input laser powers that ranged from 4 to 8 mJ/cm2 in living mice. (G) Quantitative analysis of photoacoustic signal intensities obtained with each group. The images are reproduced with permission from ref. [103].
Figure 6rGO–AuNP–PEG for PAI in the NIR-II window. (A) Schematic diagram of rGO–AuNP–PEG synthesis and PAI-guided PTT for cancer ablation in the NIR-II window. (B) TEM images, (C) hydrodynamic distribution, (D) UV–vis spectra, and (E) SERS spectra of rGO–AuNPs. (F) PA images and (G) PA amplitude after 1250 nm laser irradiation. (H) In vivo SERS signal of the tumor and its surrounding tissues to determine the boundary between tumor and normal tissue. The images are reproduced with permission from ref. [105].
G-based PAI. Each research was classified by G types, modification, abbreviation, theragnosis multimodalities, PA signal enhancement, novelties, maximum cytotoxicity concentration, and test species. AuNP, gold nanoparticle; APTES, 3-aminopropyltriethoxysilane; AuNS, gold nanostar; BSA, bovine serum albumin; CCK-8, cell counting kit 8; CS, chitosan; DODAB, dimethyldioctadecylammonium bromide; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOX, doxorubicin; FA, folic acid; FL, fluorescence; GNP, graphene nanoparticle; GQD, graphene quantum dot; GSP, gold superparticle; ICG, indocyanine green; IONP, iron oxide nanoparticle; MRI, magnetic resonance imaging; NR, nanorod; ND, nanodiamond; NIR, near infrared; O-MWGNR, oxydized graphene multi-walled nanorod; PAA, polyacrylic acid; PBS, phosphate-buffered saline; PDA, polydopamine; PEG, polyethylene glycol; PET, positron emission tomography; PT, photothermal; PTT, photothermal therapy; PVP, polyvinylpyrrolidone; US, ultrasound; SERS, surface-enhanced Raman scattering; rGO, reduced graphene oxide; TPI, two-photon imaging.
| Types | Materials Modification | Multimodalities | PA Enhancement | Novelties | Cytocompatible Concentration | Test Species | Ref. |
|---|---|---|---|---|---|---|---|
| GO | ICG and FA | PTT | 10/PBS at cell | High absorbance in the NIR region and cancer targetability | ≤20 μg/mL | HeLa | [ |
| ICG and integrin αvβ3 | FL | 5/GO at water | FL quenching via FL resonance energy transfer, selective tumor cell targetability, and apoptosis-mediated cancer ablation | ≤21.5 μg/mL | U87-MG | [ | |
| FA and CS | PTT | N/A | Stability in water and biodistribution and long-term observation of tumor recurrence inhibition | N/A | MDA-MB-231-BALB/c nude | [ | |
| Bi2Se3 and PVP | CT, PTT | N/A | Little hemolytic activity and in vivo toxicity and hydrophilicity | ≤150 μg/mL | HeLa-BALB/c nude | [ | |
| MnWO4 and PEG | MRI, PTT, chemotherapy | N/A | High drug loading capacity, pH- and NIR-stimulated drug release, and biodistribution and water content | ≤200 μg/mL | HUVEC, 4T1, and 4T1-athymic nude | [ | |
| Silica and AuNP | FL | 2.3/AuNP@SiO2 at water | Controllable photoluminescence, high-resolution PA signal, and size-dependent electromagnetic field intensity | N/A | N/A | [ | |
| APTES, silica, and PAA | TPI | N/A | High dose of dye loading and TPI for high-resolution depth penetrating imaging | N/A | HeLa, chicken breast | [ | |
| rGO | AuNR | PTT | 2.5/AuNR at PBS | Higher light absorption and electromagnetic field generation and simultaneous application by overlapping absorbance peak for PA and US application | N/A | BALB/c mice | [ |
| ICG and PDA | PTT | 20/GO at mouse tumor | Enhanced light absorbance by incorporation of ICG and In vivo tumor suppression without toxicity | N/A | 4T1 and 4T1-BALB/c | [ | |
| DOX and AuNR | FL, US, PET, PTT, chemotherapy | 20/AuNR | Sequential drug release system, high drug loading capacity, and exceptional versatility | ≤6.4 μg/mL | U87 MG and U87 MG-mouse | [ | |
| AuNP and PEG | SERS, PTT | Mouse ovarian cancers | Availability in the second NIR region by plasmonic coupling and fast clearance due to particle dissociation | N/A | SKOV-3 and SKOV-3-BALB/c nude | [ | |
| DODAB/DOPE–FA and AuNS | PTT | Mouse pancreatic tumor | PAI-guided PT/gene synergistic therapy (G12V delivery) and receptor-mediated cancer targeting | N/A | Capan-1 and Capan-1-BALB/c nude | [ | |
| GSP and PEG | PTT, US | 10/PBS | Exceptional chemical properties by plasmonic coupling of the self-assembled composites and GO-GSP emulsion method | ≤100 μg/mL | U87MG and U87MG-BALB/c nude | [ | |
| BSA | US, PTT | 1.5/blood at mouse tumor | High stability and low cytotoxicity and passive targeting | ≤80 mg/L | MCF-7 and MCF-7-mouse | [ | |
| IONP and PEG | FL, MRI | N/A | Strong NIR absorbance and superparamagnetic properties | N/A | 4T1-mouse | [ | |
| GQD | Nitrogen and FA | FL, PTT | 3/N–GQD at cells | Uniform and small size (5 nm), strong quantum yield, and low cytotoxicity | ≤500 μg/mL | HeLa and A549 | [ |
Figure 7RGD–AuNR/MWCNT conjugate for targeted PAI of gastric cancer. (A) Schematic diagram of synthesis and application of RGD–AuNR/MWCNT in mouse gastric cancer vessel visualization. (B) TEM and (C) HR–TEM images of AuNR/MWCNT. (D) UV–vis spectra of pristine MWCNT and AuNR/MWCNT. The inset shows the magnification in the region of 400~800 nm. (E) Photoacoustic images of different post-injection times. (F) TEM images of RGD–AuNR/MWCNT inside the MGC803 cells. The images are reproduced with permission from ref. [142].
CNT-based PAI. Each piece of research is classified by CNT types, modification, abbreviation, theragnosis multimodalities, PA signal enhancement, novelties, maximum cytotoxicity concentration, and test species. CNTR, carbon nanotube ring; LBL, layer-by-layer; CD, carbon dot; CND, carbon nanodot; CNS, carboneous nanosphere; Cur, curcumin; HA, hyaluronic acid; SLN, sentinel lymph node; PDDA, poly (diallyl dimethyl ammonium chloride); PLGA, poly(lactic-co-glycolic acid); PL-PEG5000, polyethylene glycol-5000 grafted phospholipid; PSS, poly (sodium 4-styrene sulfonate); RGD, cyclic Arg-Gly-Asp.
| Types | Materials Modification | Multimodalities | PA Enhancement | Novelties | Cytocompatible Concentration | Test Species | Ref. |
|---|---|---|---|---|---|---|---|
| MWCNT | RGD peptides and silica/AuNR | PTT | N/A | Good water solubility, cell targetability, and in vivo gastric cancer cell imaging | ≤200 μg/mL | MGC803, GES-1, MGC803-BALB/c nude | [ |
| SWCNT | RGD peptides and silica/AuNR | PTT | N/A | Good water solubility, cell targetability, and in vivo gastric cancer cell imaging | ≤200 μg/mL | MGC803, GES-1, MGC803-BALB/c nude | [ |
| N/A | N/A | 4/blood | SLN visualization | N/A | Sprague–Dawley rat | [ | |
| PLGA | Micro CT | N/A | Availability as tissue engineering scaffold multiscale PAI | N/A | N/A | [ | |
| ICG | FL | 2/ICG at mouse breast tumor | Detailed optical characterization of SWCNT-reinforced probes | N/A | 4T1 Luc, 4T1 Luc-BALB/c | [ | |
| ICG and RGD | N/A | 300/SWCNT at mouse subcutaneous region | αvβ3-integrin-mediated cancer targetability and enhanced optical absorbance signal duration | N/A | Nude | [ | |
| RGD and PL-PEG5000 | N/A | 8/SWCNT at ex vivo mouse tumor | Tumor targetability, non-invasive imaging of tumor, and absorbance in lower NIR window | N/A | U87MG-BALB/c nude | [ | |
| CNTR, redox-active polymer, and AuNP | Optical microscopy, Raman microscopy | 6/CNTR at water | Signal enhancement via local electrical field by SERS | N/A | U87MG cell and U87MG-nude | [ | |
| PDDA, PSS, AuNP, and silica microsphere | Raman microscopy | N/A | AuNP–CNT multilayer assemble by LBL technique, strong absorption in NIR and visible region, and ex vivo mouse brain imaging | N/A | Human fibroblast C57Bl/6 | [ |
Figure 8C225–PNDs for PAI and in vivo breast cancer ablation. (A) Proposed formation pathway of PNDs and the synthetic routes of C225–PNDs. (B) TEM image of PNDs with a corresponding size distribution histogram. (C) UV–vis spectra and (D) emission spectra (λex = 440 nm) of PNDs, C225–PNDs, and 5,10,15,20-tetrakis (4-aminophenyl) porphyrin (TAPP). (E) PA imaging and (F) relative PA intensity of C225–PNDs in the tumor at different time points. (G) Relative tumor volume. The images are reproduced with permission from ref. [165].
CNP-based PAI. Each piece of research is classified by CNP types, modification, abbreviation, theragnosis multimodalities, PA signal enhancement, novelties, maximum cytotoxicity concentration, and test species. HER2, epidermal growth factor receptor 2; HPPA, 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-α; PS, protamine sulfate.
| Types | Materials Modification | Multimodalities | PA Enhancement | Novelties | Cytocompatible Concentration | Test Species | Ref. |
|---|---|---|---|---|---|---|---|
| CD | Porphyrin and Cetuximab | PDT | N/A | Water stability, strong UV–vis and NIR abruption, and deep tissue penetration with high spatial resolution | ≤100 μg/mL | HCC827, H23, MDA-MB-231, HBL-100, MDA-MB-231-mouse | [ |
| BSA–Cu2+–Gd3+ complex and HPPH | FL, MRI, PTT, PDT | N/A | In vivo mouse toxicity evaluation and decreased intracellular ROS generation | ≤200 μg/mL | A549-BALB/c nude | [ | |
| Mn and NCD | FL, PTT | N/A | Long emission wavelength and low hemolysis | ≤1000 μg/mL | 4T1-BALB/c mice | [ | |
| CND | AuNR and silica | FL, PDT, PTT | N/A | Chemical stability in a physiological environment and prevent absolute quenching of the FL | ≤100 μg/mL | B16-F0 and B16-F0-nude | [ |
| Nitrogen | PTT | 2/AuNR at water | Photostability, biodegradability, and SLN visualization | N/A | BALB/c nude | [ | |
| CNS | glucose | PTT | 2.5/preinjection at mouse tumor | First investigation of CNS as PAI probe and controllable size of fabricated CNS | ≤320 μg/mL | PC-3M-IE8, 4T1 and 4T1-nude | [ |
| CNP | Honey, polysolvate, and PEG | N/A | N/A | One-pot green synthesis, markedly small probe for SLN imaging, rapid clearance properties, and rapid signal enhancement | N/A | Nude | [ |
| ND | HA, PS, Cur, and IR780 | FL, PTT, PDT | In vivo mouse tumor | Uniform size, high drug-loading ability, excellent colloidal stability, decreased hemolysis, and in vivo mouse toxicity evaluation | ≤100 μg/mL | MDA-MB-231 and MDA-MB-231-mouse | [ |